The German chemical giant Bayer reportedly talks to the American Elanco Animal Health about an amalgamation of animal health activities. Reuters news agency reports based on insiders. The animal health branch of Bayer could well yield up to € 8 billion. Bayer sells veterinary products for both pets and cattle. The section has reportedly attracted interest from parties such as KKR, CVC Capital Partners, Advent International, Blackstone Group, EQT Partners and Permira. “Bayer is on track with its plans to leave the animal health sector,” the group said in a statement. “After a strategic assessment of exit options, the focus is primarily on a sale. However, Bayer also continues to consider all value-maximizing options.” Bayer has been under great pressure lately about the controversial weed killer Roundup. There are countless lawsuits from people who claim they have had cancer. Through the takeover of owner Monsanto, Roundup came under the control of Bayer, which will also receive the corresponding billions of billions.